This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Critical Care Drugs Market

Market Insights on Critical Care Drugs covering sales outlook, demand forecast & up-to-date key trends

Critical Care Drugs Market by Drug Type, End User & Region - Forecast 2022 – 2032

Critical Care Drugs Market Overview (2022-2032)

[250 Pages Report] The global sales of critical care drugs market are projected to grow at a steady CAGR of around 5% to 6% between 2022 and 2032, generating substantial revenues by the end of the forecast period. Growth in the market is attributable to the increasing prevalence of various chronic diseases across the world along with rising need for better pain management during complex surgeries.

Report Attribute

Details

Critical Care Drugs Market Projected Growth Rate (2022-2032)

5% - 6% CAGR

Critical care drugs are medicines used in an emergency for treating patients with life threatening injuries and illnesses. These types of drugs are mostly used in specific care units such as coronary care units and intensive care units.

Numerous critical care drugs such as opioids, sedatives, and benzodiazepines are being increasingly used across trauma centers and hospitals for saving the lives of patients as well as for helping them to recover from serious injuries and illnesses. Apart from these, several life-saving drugs including adrenaline, sodium bicarbonate, calcium gluconate, etc. also fall in the critical care drugs category.

Critical care drugs can also be used for various symptoms or conditions like chest pain, injuries, cardiac arrest etc. Rising prevalence of life-threatening diseases and accidents is a major factor boosting the sales of critical care drugs.

Similarly, rapid expansion of healthcare industry coupled with increasing research and development activities for introducing new critical care drugs will further expand the size of critical care drugs in future.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Factors are Pushing the Sales of Critical Care Drugs?

Increasing prevalence of critical illnesses across the world, rise in the number of road accidents, an upsurge in surgeries, and introduction of novel critical care therapeutics are some of the major factors boosting the sales of critical care drugs.

Critical care drugs have become essential medicines used across intensive care units for treating patients. Consumption of these drugs relieves pain and helps patients to recover at faster speeds.

Rising incidence of road accidents is emerging as a key factor in boosting the growth of critical care drugs market and the trend is likely to continue in the future. According to the Centers for Disease Control and Prevention (CDC), each year around 1.35 million people are killed on roadways across the world.

Similarly, increasing number of surgeries performed across the world will continue to fuel the adoption of critical care drugs during the forecast period. Critical care drugs like opioids, morphine, sedatives, and anesthetics are being increasingly used for pain management during and after surgeries.

In addition to this, increase in the number of end user verticals such as intensive care units (ICUs), coronary care units (CCUs), operation theaters, and trauma centers is anticipated to create growth prospects within the global critical care drugs market in the forthcoming years.

What are the Challenges Faced by the Critical Care Drugs Industry?

Although critical care drugs have become essential emergency products, there are various factors that are likely to act as restraints for market growth. Some of these factors are the side effects associated with critical care drugs and unavailability of various products across some regions.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why is Demand for Critical Care Drugs Rising Across North America?

North America was the largest market for critical care drugs in 2022 and is likely to retain its top position during the forecast period. Growth in the market is attributable to the heavy presence of leading pharmaceutical giants, increasing incidence of chronic diseases and accidents, well established healthcare industry, and easy availability of various critical care drugs.

Demand for critical care drugs is particularly high across the United States due to rising patient pool and increasing usage of critical care drugs during surgeries. According to the Society of Critical Care Medicine (SCCM), over 5 million patients are admitted annually to U.S. ICUs for the management of injuries or illness, monitoring support of breathing or circulation; maximization of comfort for dying patients and stabilization of life-threatening medical problems.

Moreover, increasing investments and efforts of leading market players based in the U.S, for developing novel critical care drugs with more effectiveness will further expand the size of critical care drugs market in future.

What is the Growth Projection for Asia Pacific Market?

According to Future Market Insights, the critical care market in Asia Pacific is slated to grow at a relatively faster CAGR over the forecast period, owing to the rapidly growing population, increasing healthcare awareness among people, rise in number of surgeries performed, and expansion of healthcare industry.

Emerging nations like China and India are experiencing high demand for critical care drugs and the trend is likely to pertain during the forecast period. These drugs are being increasingly used across hospitals and ambulatory and trauma centers to critically ill patients and relieve pain during surgeries. Rise in number of diseases and surgeries will therefore continue to push the sales of critical care drugs across these nations in future.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Market Competition

Some of the key participants present in the global critical care drugs market include Pfizer Inc., Abbott, Cadila Pharmaceutica, Neon Laboratories Limited, Triveni chemicals, Haffkine Bio-Pharmaceutical Corporation Ltd., and Cambrex Corporation among others.

These key players are vigorously investing in research and development activities to introduce novel critical care drugs with better efficiency and lower costs. Moreover, they have adopted various organic and inorganic strategies such as partnerships, acquisitions, strengthening of distribution channels and establishment of new facilities across key attractive regions to expand tehri global footprint.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth Rate

CAGR of 5% - 6% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Million, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Type
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Pfizer Inc.
  • Abbott
  • Cadila Pharmaceutica
  • Triveni chemicals
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Neon Laboratories Limited
  • Cambrex Corporation

Customization

Available Upon Request

Key Segments Profiled in the Critical Care Drugs Industry Survey

By Drug Type:

  • Opioids
  • Naloxone
  • Fentanyl
  • Benzodiazepines
  • Diazepam
  • Pethidine
  • Midazolam
  • Lorazepum
  • Flumazenil
  • Sedatives
  • Anesthetics
  • Morphine
  • Others

By End User:

  • Intensive care unit (ICU)
  • Coronary Care Unit (CCU)
  • Operation Theatres
  • Trauma Centers

Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global sales of critical care drugs market to rise at around 5% to 6% CAGR through 2032.

Asia Pacific is expected to emerge as the most attractive market for the manufacturers of critical care drug manufacturers during the forecast period.

Pfizer Inc., Abbott, Cadila Pharmaceutica, and Triveni chemicals, are some prominent critical care drugs manufacturers

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. Value Chain Analysis

        3.5.1. Profit Margin Analysis

        3.5.2. Service Providers

    3.6. PESTLE and Porter’s Analysis

    3.7. Regulatory Landscape

        3.7.1. By Key Regions

        3.7.2. By Key Countries

    3.8. Regional Parent Market Outlook

4. Global Critical Care Drugs Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032

        5.3.1. Analgesics

        5.3.2. Sedatives/Reversal Agents

        5.3.3. Neuromuscular Blocking Agents

        5.3.4. Vasoactive and Inotropic Agent

        5.3.5. Antihypertensive Drugs

        5.3.6. Anticoagulants

        5.3.7. Antiarrhythmic Drugs

        5.3.8. Adrenergic Agonist Drugs

        5.3.9. Anti-infective Drugs

        5.3.10. Antibiotic Drugs

        5.3.11. Diuretics

        5.3.12. ACE Inhibitors

        5.3.13. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032

    5.6. Deep-dive segmentation will be available in the sample on request

6. Global Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Renal Disorders

        6.3.2. Cardiovascular Disorders

        6.3.3. Pulmonary Disease

        6.3.4. Infectious Disease

        6.3.5. Gastrointestinal Disorders

        6.3.6. Neurologic Disorders

        6.3.7. Hematologic and Oncologic Disorders

        6.3.8. Surgery and Trauma

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

    6.6. Deep-dive segmentation will be available in the sample on request

7. Global Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        7.3.1. Intensive Care Units (ICU)

        7.3.2. Cardiac Care Units (ICU)

        7.3.3. Operation Theatres

        7.3.4. Trauma Centers 

    7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

    7.5. Absolute $ Opportunity Analysis By End User, 2022-2032

    7.6. Deep-dive segmentation will be available in the sample on request

8. Global Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. East Asia

        8.3.5. South Asia & Pacific

        8.3.6. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Indication

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Indication

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Mexico

            10.2.1.2. Brazil

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Indication

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Indication

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. Italy

            11.2.1.3. France

            11.2.1.4. U.K.

            11.2.1.5. Spain

            11.2.1.6. BENELUX

            11.2.1.7. Russia

            11.2.1.8. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Indication

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Indication

        11.3.4. By End User

    11.4. Key Takeaways

12. East Asia Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Type

        12.2.3. By Indication

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Indication

        12.3.4. By End User

    12.4. Key Takeaways

13. South Asia & Pacific Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. ASEAN

            13.2.1.3. Australia and New Zealand

            13.2.1.4. Rest of South Asia & Pacific

        13.2.2. By Drug Type

        13.2.3. By Indication

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Indication

        13.3.4. By End User

    13.4. Key Takeaways

14. MEA Critical Care Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. Turkey

            14.2.1.3. South Africa

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Type

        14.2.3. By Indication

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Indication

        14.3.4. By End User

    14.4. Key Takeaways

15. Key Countries Critical Care Drugs Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2021

            15.1.2.1. By Drug Type

            15.1.2.2. By Indication

            15.1.2.3. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2021

            15.2.2.1. By Drug Type

            15.2.2.2. By Indication

            15.2.2.3. By End User

    15.3. Mexico

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2021

            15.3.2.1. By Drug Type

            15.3.2.2. By Indication

            15.3.2.3. By End User

    15.4. Brazil

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2021

            15.4.2.1. By Drug Type

            15.4.2.2. By Indication

            15.4.2.3. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2021

            15.5.2.1. By Drug Type

            15.5.2.2. By Indication

            15.5.2.3. By End User

    15.6. Italy

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2021

            15.6.2.1. By Drug Type

            15.6.2.2. By Indication

            15.6.2.3. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2021

            15.7.2.1. By Drug Type

            15.7.2.2. By Indication

            15.7.2.3. By End User

    15.8. U.K.

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2021

            15.8.2.1. By Drug Type

            15.8.2.2. By Indication

            15.8.2.3. By End User

    15.9. Spain

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2021

            15.9.2.1. By Drug Type

            15.9.2.2. By Indication

            15.9.2.3. By End User

    15.10. BENELUX

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2021

            15.10.2.1. By Drug Type

            15.10.2.2. By Indication

            15.10.2.3. By End User

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2021

            15.11.2.1. By Drug Type

            15.11.2.2. By Indication

            15.11.2.3. By End User

    15.12. China

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2021

            15.12.2.1. By Drug Type

            15.12.2.2. By Indication

            15.12.2.3. By End User

    15.13. Japan

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2021

            15.13.2.1. By Drug Type

            15.13.2.2. By Indication

            15.13.2.3. By End User

    15.14. South Korea

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2021

            15.14.2.1. By Drug Type

            15.14.2.2. By Indication

            15.14.2.3. By End User

    15.15. India

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2021

            15.15.2.1. By Drug Type

            15.15.2.2. By Indication

            15.15.2.3. By End User

    15.16. ASEAN

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2021

            15.16.2.1. By Drug Type

            15.16.2.2. By Indication

            15.16.2.3. By End User

    15.17. Australia and New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2021

            15.17.2.1. By Drug Type

            15.17.2.2. By Indication

            15.17.2.3. By End User

    15.18. GCC Countries

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2021

            15.18.2.1. By Drug Type

            15.18.2.2. By Indication

            15.18.2.3. By End User

    15.19. Turkey

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2021

            15.19.2.1. By Drug Type

            15.19.2.2. By Indication

            15.19.2.3. By End User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2021

            15.20.2.1. By Drug Type

            15.20.2.2. By Indication

            15.20.2.3. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Type

        16.3.3. By Indication

        16.3.4. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Pfizer Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

                17.1.1.5.2. Product Strategy

                17.1.1.5.3. Channel Strategy

        17.1.2. Sanofi SA

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

                17.1.2.5.2. Product Strategy

                17.1.2.5.3. Channel Strategy

        17.1.3. Johnson & Johnson

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

                17.1.3.5.2. Product Strategy

                17.1.3.5.3. Channel Strategy

        17.1.4. Merck & Co., Inc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

                17.1.4.5.2. Product Strategy

                17.1.4.5.3. Channel Strategy

        17.1.5. Mylan N.V.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

                17.1.5.5.2. Product Strategy

                17.1.5.5.3. Channel Strategy

        17.1.6. GlaxoSmithKline plc.

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

                17.1.6.5.2. Product Strategy

                17.1.6.5.3. Channel Strategy

        17.1.7. Eli Lilly and Company

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

                17.1.7.5.2. Product Strategy

                17.1.7.5.3. Channel Strategy

        17.1.8. Novartis AG

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

                17.1.8.5.2. Product Strategy

                17.1.8.5.3. Channel Strategy

        17.1.9. Allergan Plc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

                17.1.9.5.2. Product Strategy

                17.1.9.5.3. Channel Strategy

        17.1.10. AstraZeneca plc. 

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

                17.1.10.5.2. Product Strategy

                17.1.10.5.3. Channel Strategy

        17.1.11. Teva Pharmaceutical Industries Ltd. 

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

                17.1.11.5.2. Product Strategy

                17.1.11.5.3. Channel Strategy

        17.1.12. Sun Pharmaceutical Industries Limited

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

                17.1.12.5.2. Product Strategy

                17.1.12.5.3. Channel Strategy

        17.1.13. Bristol-Myers Squibb Company

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

                17.1.13.5.2. Product Strategy

                17.1.13.5.3. Channel Strategy

        17.1.14. Bayer AG

            17.1.14.1. Overview

            17.1.14.2. Product Portfolio

            17.1.14.3. Profitability by Market Segments

            17.1.14.4. Sales Footprint

            17.1.14.5. Strategy Overview

                17.1.14.5.1. Marketing Strategy

                17.1.14.5.2. Product Strategy

                17.1.14.5.3. Channel Strategy

        17.1.15. Daiichi Sankyo Company, Limited 

            17.1.15.1. Overview

            17.1.15.2. Product Portfolio

            17.1.15.3. Profitability by Market Segments

            17.1.15.4. Sales Footprint

            17.1.15.5. Strategy Overview

                17.1.15.5.1. Marketing Strategy

                17.1.15.5.2. Product Strategy

                17.1.15.5.3. Channel Strategy

        17.1.16. Gilead Sciences, Inc.

            17.1.16.1. Overview

            17.1.16.2. Product Portfolio

            17.1.16.3. Profitability by Market Segments

            17.1.16.4. Sales Footprint

            17.1.16.5. Strategy Overview

                17.1.16.5.1. Marketing Strategy

                17.1.16.5.2. Product Strategy

                17.1.16.5.3. Channel Strategy

        17.1.17. F. Hoffmann-La Roche Ltd

            17.1.17.1. Overview

            17.1.17.2. Product Portfolio

            17.1.17.3. Profitability by Market Segments

            17.1.17.4. Sales Footprint

            17.1.17.5. Strategy Overview

                17.1.17.5.1. Marketing Strategy

                17.1.17.5.2. Product Strategy

                17.1.17.5.3. Channel Strategy

        17.1.18. Boehringer Ingelheim GmbH

            17.1.18.1. Overview

            17.1.18.2. Product Portfolio

            17.1.18.3. Profitability by Market Segments

            17.1.18.4. Sales Footprint

            17.1.18.5. Strategy Overview

                17.1.18.5.1. Marketing Strategy

                17.1.18.5.2. Product Strategy

                17.1.18.5.3. Channel Strategy

        17.1.19. Vertex Pharmaceuticals, Inc.

            17.1.19.1. Overview

            17.1.19.2. Product Portfolio

            17.1.19.3. Profitability by Market Segments

            17.1.19.4. Sales Footprint

            17.1.19.5. Strategy Overview

                17.1.19.5.1. Marketing Strategy

                17.1.19.5.2. Product Strategy

                17.1.19.5.3. Channel Strategy

        17.1.20. Sumitomo Dainippon Pharma Co., Ltd. 

            17.1.20.1. Overview

            17.1.20.2. Product Portfolio

            17.1.20.3. Profitability by Market Segments

            17.1.20.4. Sales Footprint

            17.1.20.5. Strategy Overview

                17.1.20.5.1. Marketing Strategy

                17.1.20.5.2. Product Strategy

                17.1.20.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Critical Care Drugs Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 3: Global Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 4: Global Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 5: North America Critical Care Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: North America Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 7: North America Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 8: North America Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 9: Latin America Critical Care Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Latin America Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 11: Latin America Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 12: Latin America Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 13: Europe Critical Care Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Europe Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 15: Europe Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 16: Europe Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 17: East Asia Critical Care Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 18: East Asia Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 19: East Asia Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 20: East Asia Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 21: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 23: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 24: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 25: MEA Critical Care Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 26: MEA Critical Care Drugs Market Value (US$ Mn) Forecast by Drug Type, 2017-2032

Table 27: MEA Critical Care Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 28: MEA Critical Care Drugs Market Value (US$ Mn) Forecast by End User, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 2: Global Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 3: Global Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 4: Global Critical Care Drugs Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Critical Care Drugs Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 6: Global Critical Care Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Critical Care Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 9: Global Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 10: Global Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 11: Global Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 12: Global Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 13: Global Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 14: Global Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 15: Global Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 16: Global Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 17: Global Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 18: Global Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 19: Global Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 20: Global Critical Care Drugs Market Attractiveness by Region, 2022-2032

Figure 21: North America Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 22: North America Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 23: North America Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 24: North America Critical Care Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Critical Care Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 26: North America Critical Care Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Critical Care Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 29: North America Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 30: North America Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 31: North America Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 32: North America Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 33: North America Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 34: North America Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 35: North America Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 36: North America Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 37: North America Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 38: North America Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 39: North America Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 40: North America Critical Care Drugs Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 42: Latin America Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 43: Latin America Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 44: Latin America Critical Care Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Critical Care Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 46: Latin America Critical Care Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Critical Care Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 49: Latin America Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 50: Latin America Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 51: Latin America Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 52: Latin America Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 53: Latin America Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 54: Latin America Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 55: Latin America Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 56: Latin America Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 57: Latin America Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 58: Latin America Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 59: Latin America Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 60: Latin America Critical Care Drugs Market Attractiveness by Country, 2022-2032

Figure 61: Europe Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 62: Europe Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 63: Europe Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 64: Europe Critical Care Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Critical Care Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 66: Europe Critical Care Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Critical Care Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 69: Europe Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 70: Europe Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 71: Europe Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 72: Europe Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 73: Europe Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 74: Europe Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 75: Europe Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 76: Europe Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 77: Europe Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 78: Europe Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 79: Europe Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 80: Europe Critical Care Drugs Market Attractiveness by Country, 2022-2032

Figure 81: East Asia Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 82: East Asia Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 83: East Asia Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 84: East Asia Critical Care Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 85: East Asia Critical Care Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 86: East Asia Critical Care Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: East Asia Critical Care Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: East Asia Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 89: East Asia Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 90: East Asia Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 91: East Asia Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 92: East Asia Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 93: East Asia Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 94: East Asia Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 95: East Asia Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 96: East Asia Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 97: East Asia Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 98: East Asia Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 99: East Asia Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 100: East Asia Critical Care Drugs Market Attractiveness by Country, 2022-2032

Figure 101: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 102: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 103: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 104: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 105: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 106: South Asia & Pacific Critical Care Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: South Asia & Pacific Critical Care Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 109: South Asia & Pacific Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 110: South Asia & Pacific Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 111: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 112: South Asia & Pacific Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 113: South Asia & Pacific Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 114: South Asia & Pacific Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 115: South Asia & Pacific Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 116: South Asia & Pacific Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 117: South Asia & Pacific Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 118: South Asia & Pacific Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 119: South Asia & Pacific Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 120: South Asia & Pacific Critical Care Drugs Market Attractiveness by Country, 2022-2032

Figure 121: MEA Critical Care Drugs Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 122: MEA Critical Care Drugs Market Value (US$ Mn) by Indication, 2022-2032

Figure 123: MEA Critical Care Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 124: MEA Critical Care Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 125: MEA Critical Care Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 126: MEA Critical Care Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 127: MEA Critical Care Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 128: MEA Critical Care Drugs Market Value (US$ Mn) Analysis by Drug Type, 2017-2032

Figure 129: MEA Critical Care Drugs Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 130: MEA Critical Care Drugs Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 131: MEA Critical Care Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 132: MEA Critical Care Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 133: MEA Critical Care Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 134: MEA Critical Care Drugs Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 135: MEA Critical Care Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 136: MEA Critical Care Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 137: MEA Critical Care Drugs Market Attractiveness by Drug Type, 2022-2032

Figure 138: MEA Critical Care Drugs Market Attractiveness by Indication, 2022-2032

Figure 139: MEA Critical Care Drugs Market Attractiveness by End User, 2022-2032

Figure 140: MEA Critical Care Drugs Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Critical Care Information Systems Market

Published : May 2017

Healthcare

Critical Care Diagnostics Market

Published : December 2016

Healthcare

Critical Care Patient Monitoring Products Market

Published : February 2022

Google translate

Critical Care Drugs Market